li id i p fili ilipidomics profiling in bi l i l m t i ... · pm p1 p3 p10 n1 n3 n10 ht drug dose...

Li id i P fili iLipidomics Profiling in High-Resolution LC-C lli i l Di iCollisional Dissocia

Bruce S KBruce S KBruce S. KBruce S. K

Dept of Neurosurgery, BrigDept of Neurosurgery, BrigDept of Surgery, HaDept of Surgery, Hag yg y

Bi l i l M t i bBiological Matrices by MS and High-Energy ti F t tiation Fragmentation

Kristal PhDKristal PhDKristal, PhDKristal, PhD

gham and Women’s Hospitalgham and Women’s Hospitalarvard Medical Schoolarvard Medical School

Industry A(Disclosure per Partne

Rel

ThermoFisher: My lab has an LTQ-Orbitrap, wefrom a Demo-test of an Exactive, and the in

collaborated for years with ESA Inc (~199collaborated for years with ESA, Inc (~199ThermoFisher. On

Unre

Additional consulting: Mead Johnson (Consui ti )inactive)

Metabolon/Metabolomics: Consu(IP agreements(IP agreements

Affiliations ers Healthcare policy):

ated

e have beta-tested SIEVE, the work I will show is nitial set-up was done in collaboration. I also 95-2005) which has since been acquired by95-2005), which has since been acquired by ngoing discussions

elated:

ultant, inactive), MARS Petcare UK (consultant, K ll, Kelloggs

ultant/Equity, Post-sales Royaltiesvia/Cornell Med)via/Cornell Med)

Macronutrients MitoMacronutrients MitoMacronutrients, MitoMacronutrients, MitoMetabolomeMetabolome DiseDise

Bruce Kristal; Susan S. Bird; IrinaBruce Kristal; Susan S. Bird; Irina; ;; ;Baranov, Caryn L. Porter, HeathBaranov, Caryn L. Porter, HeathSniatynskiSniatynski; Diane Sheldon; ; Diane Sheldon; VasVasWalter C Willett Susan E HankWalter C Willett Susan E HankWalter C. Willett, Susan E. HankWalter C. Willett, Susan E. Hank

Brigham and Women’s HospitalBrigham and Women’s Hospitalg pg pHarvard School of Public HealthHarvard School of Public Health

ochondria and Bloodochondria and Bloodochondria and Blood ochondria and Blood ase Risk Profiles ase Risk Profiles

G G StavrovskayaStavrovskaya, Sergei , Sergei yy , g, gher Greenberg, Matthew J. her Greenberg, Matthew J. antant R. R. MarurMarur; Wayne R. Matson, ; Wayne R. Matson,

kinsonkinsonkinsonkinson

l, Harvard Medical School, l, Harvard Medical School, , ,, ,h, Bedford VAh, Bedford VA

This talk This talk bottlenecks abottlenecks a

is about is about and leverageand leveragegg

GEGE

NIH GenEnvironmen

EIEI

nes and nt Initiative

Suboptimal macroare arguably the maare arguably the ma

stressor in indivtwestern s

onutrient choices ajor environmentalajor environmental viduals living in

i tisocieties

Diet is lDiet is ldiseadisea

linked tolinked to se riskse risk

Reactive sReactive slinked to dlinked to d

species arespecies are disease riskdisease risk

Diets caDiets careactivereactive

an affectan affect e speciese species

Mitochproduce

an

hondria e energy, gy

nd…

Mitochondria aremetabolism anmetabolism an

reactive specief ti i ifunction impaire

many disy

e linked to calcium nd production ofnd production of es; mitochondrial

d b l ied or abnormal in ease states

Di tDiet

Disease

Mit h d iMitochondria

Reactive S iSpecies

Di t?

Diet

Disease

Mit h d i?

Mitochondria

Reactive S iSpecies

HypotHypot

Diet-associatmitochondriamitochondriadiet-associate

didiseas

thesisthesis

ted effects on a are linked toa are linked to ed changes in

i kse risk.

How do we sHow do we sHow do we sHow do we sbiological/clinbiological/clin

How do we addresHow do we addreshumans, where our humans, where our

and analyze the sand analyze the syy

study complexstudy complexstudy complex study complex nical problems?nical problems?

s such questions in s such questions in ability to manipulate ability to manipulate

system is limited?system is limited?yy

High ThHigh ThHigh ThHigh Thand/or Data Dand/or Data D

•• Genomics/SNGenomics/SNGenomics/SNGenomics/SN•• mRNA expresmRNA expres•• ProteomicsProteomics•• Small metaboSmall metaboSmall metaboSmall metabo

roughputroughputroughputroughputDensity StudiesDensity Studies

NPsNPsNPsNPsssion arraysssion arrays

olitesolitesolitesolites

MetaboMetaboThTh i fi fThe The ––omics face omics face

Measurement of chanMeasurement of chanlow molecular weightlow molecular weight

given set of given set of ggFieFie

lomics: lomics: f bi h i tf bi h i tof biochemistryof biochemistry

ges in populations of ges in populations of g p pg p pt metabolites under a t metabolites under a conditions conditions hnhn

HEALTH

TRA

HEALTHSTATE

ME

DISEASE STATE

GENOME

EN

VIR

ANSCRIPTOME

RO

NM

EN

PROTEOME

NT

ETABOLOME

Core ACore AAim 1 To determine the effectsAim 1 To determine the effects

and carbohydrate compophysiology (24 diets)

Aim 2 To determine the effectsand carbohydrate compoy pmetabolome

Aims 3 and 4: To determine the exAims 3 and 4: To determine the exto/presence of each dietmitochondrial property pp p y pand breast cancer (Aim 4control studies nested w

AimsAimss of dietary changes in fatty acid s of dietary changes in fatty acid osition on mitochondrial

s of dietary changes in fatty acid osition on the plasma p

xtent to which adherence xtent to which adherence , dietary constituent, and predict type II diabetes (Aim 3) p yp ( )4) in previously profiled case

within the Nurses' Health Study

Determine diets that are associated with specific m

tiAim 1

Assess mitochondrial physiology

Determine metabolomic adiet profiles that are assoc

properties

Determine diet componenthat are associated with smitochondrial properties

Feed rats defined diets

Analyze plasma metabolome

Determine metabolomic pthat are associated with sdiet components

diet profiles that are assocwith specific mitochondriaproperties

Aim 2

Determine metabolomic pthat are associated with sdiets

diet components

Product (BiomarkeProduct (BiomarkeDevelopment

mitochondrial

Hypothesis test: The hypothesis linking mitochondria and diet and disease will be rejected if markers of mitochondrial phenotypes fail to predict disease at least as well as dietary markers and/or if they yield discordant predictions at the population or individual level

and ciated

ntsspecific

Determine diets that are associated

Determine mitochondrial propertiesthat are associated with increased risk of disease

at the population or individual level.

Aims 3 and 4

Determine if profiles predict diabetes and breast cancer in NHS

profiles specific

ciated al

Determine diet components that are associated with increased risk of disease

Determine diets that are associated with increased risk of disease

Aims 3 and 4

profiles specific

Determine if profiles reflect diet and diet constituents within the limits of the food frequency data collected in the Nurses’ H lth St d

er) Product (Biomarker)

Health Study

Product (Biomarker)er) Product (Biomarker)Outcome Validation

Product (Biomarker)Target Validation

BioloBiolo

GAnalyticalAnalytical

G

ChemistryChemistry

ogyogygygy

EIData Data

EI

AnalysisAnalysis

Core PLANN

Food

GRats

Res

Ca2+ cRat liver mitos

Dru

Stored Samples Bioc

NED Assays

Consumed} R-

Growth }spiration

-scr

}challenge

ripts}ug Study

s}chemistry

Bi lBi lBiology Biology ––multiplemultiplemultiplemultiple


G

ChemistryChemistry

tt–– rats on rats on e dietse dietse dietse diets

EIData Data

EI

AnalysisAnalysis

DieDieDieDie

Carbohydrates: DiffeCarbohydrates: Diffehigh (high (egeg, bagels),, bagels),g (g ( gg, g ),, g ),

moderately low, lowmoderately low, low

Fats: Differ Fats: Differ Saturated (Saturated (egeg creacreaSaturated (Saturated (egeg, crea, crea

MUFA (MUFA (egeg, olive oil), w6:w, olive oil), w6:woil) at 50:1oil) at 50:1oil) at 50:1oil) at 50:1

etsetsetsets

er by er by glycemicglycemic indexindex, moderately high , moderately high , y g, y gw (w (egeg, whole grains), whole grains)

by major fatby major fatam cheese) Transam cheese) Transam cheese), Trans, am cheese), Trans, w3 (w3 (egeg, vegetable oils/fish , vegetable oils/fish 1 10:1 1:11 10:1 1:11, 10:1, 1:11, 10:1, 1:1

Diet and Anfat breakdown SFA TRANS MUFA PUFA

(ω-6/ω-3)

6 Fat Groups

1 X - - -2 - X - -

3 - - X -4 - - - 50:1

5 - - - 10:15 - - - 10:1

6 - - - 1:1

24 Diet

2 th ld l FBNF1 t ( 8/diAnimal Models

24 Diet

2 month old male FBNF1 rats (n=8/diAnimals fed ad libitumSacrificed after 8 weeks

Serum collected Se u co ec edLiver mitochondria isolated

Entire study done twice

nimal Study

Carbohydrate breakdown

Sucrose Starch

4 Carbohydrate Groups

breakdown High Sucrose 100 % 0 %Moderate High Sucrose 43 % 22 %

Moderate Low Sucrose 22 % 43 %Low Sucrose 0 100 %

ts Total

t)

ts Total192

Samples Totalet) Samples Total

Bi lBi l ttBiology Biology –– ratsratsdiets + phdiets + phdiets + phdiets + ph


G

ChemistryChemistry

lti llti ls on multiple s on multiple hysiologyhysiologyhysiologyhysiology

EIData Data

EI

AnalysisAnalysis

Animal PhAnimal Ph

EchoMRIEchoMRI –– BodBodBody weight, fooBody weight, fooRespiratory quotRespiratory quotRespiratory quotRespiratory quot

Home cagHome cag

hysiologyhysiology

dy compositiondy compositiony py pod consumptionod consumptiontient fuel usagetient fuel usagetient, fuel usagetient, fuel usage

ge activityge activity


AnalyticalAnalytical GAnalyticalAnalyticalChemistryChemistry

G

----CoularrayCoularrayCoularrayCoularray


EIData Data

EI

AnalysisAnalysis

CoulaCoula•• HPLC separations couHPLC separations cou

CoulaCoula•• HPLC separations couHPLC separations cou

array detectorsarray detectors

•• Sensitivity to femSensitivity to fem•• Resolution of coResolution of co--•• Resolution of coResolution of co--•• Qualitative charaQualitative chara

BiochemicalBiochemicalBiochemicalBiochemicalPurityPurity

arrayarrayupled with coulometricupled with coulometric

arrayarrayupled with coulometric upled with coulometric

mtomole levels of analytemtomole levels of analyte--eluting peakseluting peaks--eluting peakseluting peaks

acterization of peaksacterization of peaksl identityl identityl identityl identity

LCLC--EC (EC (CCLCLC--EC (EC (CCHigh senHigh senHigh senHigh senHigh prHigh pr

RedoxRedox spsp

No structuraNo structuraNo structuraNo structuraLow throLow thro

Diffi lt tDiffi lt tDifficult toDifficult to

oularrayoularray))oularrayoularray))nsitivitynsitivitynsitivity nsitivity

recisionrecision

pecificitypecificity

l informationl informationl informationl informationoughputoughput

t tt to automateo automate

Putative Bio

Dietary CoDietary Co

omarkers for

omponentsomponents


GAnalyticalAnalyticalChemistryChemistry

G

----CoularrayCoularray


EIData Analysis Data Analysis

––

EI

VisualizationsVisualizations

Analytical

By Diet Group

Mean

By fat/carb

Mean

By Diet Group

Median

By fat/carb

Median

Bar PlotsBar Plots

Bar Plots

Compare wCompare wdiets o

with prototypewith prototype of interest

By individualBy individualrats

SeasonalityStudy

Heat MapsTrans MUFA

ω3>ω6 ω6

s – Fats

SAT

6>ω3

Heat Maps – GlyLow>highLow>high

ycemic IndexHigh>low

BiomarkBiomarkas plap

ker pieceker piece anned


AnalyticalAnalytical GAnalyticalAnalyticalChemistryChemistry

++

G++

mitochondrial mitochondrial physiologyphysiologyphysiologyphysiology


EIData AnalysisData Analysis

EIData AnalysisData Analysis

Partial Mitochondria(ROS E(ROS, Enzyme

Respiratio2 3 4 U 23 34 24 3U PO

2 3 4 U 23 34 24 3U POO2 3 4 U 23 34 24 3U PO

2 3 4 U 23 34 24 3U PO

CalciumDose INH OXIDANTC2 C5 C10 C20 M CS Iso TB PL

Dose INH OXIDANT

k1 ΔΨnk2 CaSWPN

l Phenotyping Panelt h )es not shown)

on panelO Pyr

AKGGM

OO GM

SucO

O

panelDRUG DOSE

N10N3N1P10P3P1PM HT DRUG DOSE

HC

Respiration Overview: Substrate //State relationships look similar

Respiration Overview: Substrate /SState relationships look similar

Cross-substrate Similarityy

40

45

1

2

Mean V2 Groups 1-5

tein

)

tein

)

Respiration

20

25

30

35

1

1

1

1

1

nsum

ed/m

in/m

g pr

ot

nsum

ed/m

in/m

g pr

ot

0

5

10

15

[Oxy

gen]

(nM

ol c

on

D401 Mean V2 D402 Mean V2 D403 Mean V2 D409 Mean V2 D412 Mean V2 D416 Mean V2 D417 Mean V2 D418 Mean V2 D420 Mean V2 D422 Mean V2 [O

xyge

n] (n

Mol

con

10 12 15 20 25 30 37

40

45

2

3

V2 Temperature (°C)

Mean V4 Groups 1-5

tein

tein

20

25

30

35

1

2

2

nsum

ed/m

in/m

g pr

ot

nsum

ed/m

in/m

g pr

ot

0 5 10 15 20 25 30 35 400

5

10

15 1

[Oxy

gen]

nM

ol c

on D401 Mean V4 D402 Mean V4 D403 Mean V4 D409 Mean V4 D412 Mean V4 D416 Mean V4 D417 Mean V4 D418 Mean V4 D420 Mean V4 D422 Mean V4 [O

xyge

n] n

Mol

con

0 5 10 15 20 25 30 35 40


80

200

Mean V3 Groups 1-5

00

20

40

60

80

0

20

40

60

80 D401 Mean V3 D402 Mean V3 D403 Mean V3 D409 Mean V3 D412 Mean V3 D416 Mean V3 D417 Mean V3 D418 Mean V3 D420 Mean V3 D422 Mean V3

0 5 10 15 20 25 30 35 40

250

300


Mean VU Groups 1-5

50

200

250

D401 Mean VU

0 5 10 15 20 25 30 35 400

50

00D401 Mean VU

D402 Mean VU D403 Mean VU D409 Mean VU D412 Mean VU D416 Mean VU D417 Mean VU D418 Mean VU D420 Mean VU D422 Mean VU

0 5 10 15 20 25 30 35 40

VU Temperature (°C)

6 0

6.5

6

7.

Mean RCR 3/2 8-4-09

4.0

4.5

5.0

5.5

6.0

4.

5.

5.

6.

6.

RC

R 3

/2

D401 Mean RCR 3/2D402 M RCR 3/2 n

RC

R 3

/4

10 15 20 25 30 35 402.0

2.5

3.0

3.5

2.

3.

3.

4.

R D402 Mean RCR 3/2 D403 Mean RCR 3/2 D409 Mean RCR 3/2 D412 Mean RCR 3/2 D416 Mean RCR 3/2 D417 Mean RCR 3/2 D418 Mean RCR 3/2 D420 Mean RCR 3/2 D422 Mean RCR 3/2

Mea

10 15 20 25 30 35 40

2.802.852.902.95

Temperature (°C)

Mean ADPO 8-4-09

2 352.402.452.502.552.602.652.702.75

Mea

n AD

PO

10 15 20 25 30 35 402.002.052.102.152.202.252.302.35M D401 Mean ADPO

D402 Mean ADPO D403 Mean ADPO D409 Mean ADPO D412 Mean ADPO D416 Mean ADPO D417 Mean ADPO D418 Mean ADPO D420 Mean ADPO D422 Mean ADPO

Temperature (°C)

5

.0

Mean RCR 3/4 8-4-09 D401 Mean RCR 3/4 D402 Mean RCR 3/4 D403 Mean RCR 3/4 D409 Mean RCR 3/4D412 Mean RCR 3/4

.5

.0

.5

.0

.5 D412 Mean RCR 3/4 D416 Mean RCR 3/4 D417 Mean RCR 3/4 D418 Mean RCR 3/4 D420 Mean RCR 3/4 D422 Mean RCR 3/4

10 15 20 25 30 35 40

.5

.0

.5

.0

10 15 20 25 30 35 40

Temperature (°C)

RCR and ADP/O(b k Y i )(broken Y axis)

Implic

• Liver mitochondrial resstable to diet – gene eg

• Far cleaner and less c• Proof of principle for g• Proof of principle for g

O t it t i• Opportunity: repeat wi• Opportunity: Platform

cation

spiration in FBNF1 very environment expt in ratspcomplex than expectedgeneral approachgeneral approach

ith th di t / d lith other diets/modelsfor mito tox studies

BuBu

Functional MTargTarg

tt…

Mitochondrial ets?ets?

Slide(s) remove( )author at bkrista

if i tif inter

ed …contact the [email protected]

t drested

Big Bottlleneck…


AnalyticalAnalyticalCC GChemistryChemistry

----CC

G

CoularrayCoularray + + IDs + software IDs + software

li id ili id i+ lipidomics+ lipidomics


EIData Data

EI

AnalysisAnalysis

LIPID MAPS C t iWhat are lipids?LIPID MAPS Categori

1.

3.Fatty Acyls (FA)

Glycerophospholipids (GP)

7

5.

7.

6.Sterols (ST)

Prenols (PR) Polyketide

es2.

Glycerolipids (GL )

4.

Sphingolipids (SP)

8.

Sphingolipids (SP)

es (PK) Sacchrolipids (SL)

LC-MS LipidoExperimenExperimen

Chromatography2.1 x 150 mm Ascentis express C18 2.7µmcolumn45⁰ CA:60:40 ACN:H2O 10mM NH4COOHA:60:40 ACN:H2O 10mM NH4COOHB:90:10 IPA:ACN 10mM NH4COOHGradient from 32% B to 97% in 30 minute260 µL/min10 µl injections

Hankemeier, JPR; 7, 4982-4991, 2008

omics Profiling tal Methodtal Method

Thermo Exactive MSHi h l ti ttim High resolution setting

50,000 (2 Hz)4.0 kV250⁰ C heated capillaryHESI ionization probe

es

HESI ionization probe300 ⁰ C

Sheath gas 30 units

Auxillary gas y g15 units

Lipid Profiling and IdeR l ti LC MS dResolution LC-MS and

Susan

Brigham and Women's

entification using High d HCD F t tid HCD Fragmentation

S. Bird

s Hospital, Boston, MA

LC-MS Profili

LC-MS full sca192 rat + 17 p192 rat + 17 p

Differentia

LC-MS with H30 eV &

Lipid iden

Diet sign

ing Workflow

an acquisitions pool samplespool samples

al analysis

HCD scanning& 60 eV

tifications

nificance

IdentificatioBatch database search

Metlin DatabaseSearch by ionization mode (ie. positive oy ( p

Narrow search by mass accuracy (ie. < 3Adduct possibilities calculated based on exact

[M+NH4]+[M+Formic Acid]-[M+Na]±[ ]

Human Metabolome Database (HMDB~7900 experimentally confirmed metabo~3800 lipid speciesSearch by ionization mode (ie. positive oy ( pAdduct possibilities calculated based on exact

Ionization of lipid classesPC [M F i A id] / [M H]PC – [M+Formic Acid]- / [M+H]+PE – [M-H]- / [M+H]+PS – [M-H]-PI – [M-H]-[ ]CL – [M-H]- / [M+NH4]+

– [M+Na]- / [M+Na]+

on of Lipids

or negative)g )3 ppm)t mass

B) v 2.5olites

or negative)g )t mass

PG – [M-H]- / [M+NH4]+4

PA – [M-H]- / [M+NH4]+FA – [M-H]- / [M+NH4]+SL – [M+Formic Acid]- / [M+H]+TG – [M+NH4]+ST – [M+NH4]+

PlasmasMitochond

ma and a a ddrial Lipids

PlasPlas

Bird, SS; Marur, VR; Sniatynski, MSerum Lipidomics Profiling using Collisional Dissociation FragmentCollisional Dissociation FragmentDetection and Characterization, Analytical Chemistry, 83:6y y,PMID: 21774539

smasma

MJ; Greenberg, HK; Kristal, BS, LC-MS and High Energy

tation: Focus on Triglyceridetation: Focus on Triglyceride

648-57, 2011.,

GlycerophosS hi li id

Serum PooN ti IRT: 0.00 - 30.02 SM: 7B

70

80

90

100

e

13.85Sphingolipids:

Fatty Acyls

Negative Ion

30

40

50

60

Relative Abu

ndan

ce 12.38

3.26

14.222.51 3.484.96

12.01 159.342.37

LysoGlycerophospholipids

0 2 4 6 8 10 12 14Time (m

0

10

20 6.44 11.100.07

7.31

RT: 0.00 - 30.02 SM: 7B

80

90

100

GlycerophosGlycerolipids:

Sphingolipids: SPositive Ion

30

40

50

60

70

Relative Abu

ndan

ce

13.6012.15

Fatty Acyls

LysoGlycerophospholipidsGlycerolipids: Monoglycerides

Sterols: Cholic Acids

0 2 4 6 8 10 12 14Time (m

0

10

20 13.912.10 3.18 11.754.81 156.2511.138.74

spholipidsG li id

ol TICsNL:8.42E6TIC MS POOL_9

: Gangliosides

2 23.68

23.05 27.065.44 24.0322 8315 69

16 18 20 22 24 26 28 30min)

22.8315.69 21.1017.00

20.7928.85

Glycerolipids: Triglycerides

23.59

23.27

NL:3.21E8TIC MS POOL_5

y p g ySterols: Cholesterol Estersspholipids

DiglyceridesSphingomyelins

Ceramides

22.9023 92

Prenols

16 18 20 22 24 26 28 30min)

23.92

5.07 19.5322.70 24.2416.52 18.48 25.32 29.80

RT MZ New Error TG (C:DB) ID % composition CV

(n=18)

1 22.51 740.6742 ‐0.37 TG(42:0)* TG(14:0/14:0/14:0) 0.128 5.35

Unique TGs in ( ) ( / / )

2 21.99 738.6590 0.25 TG(42:1)* TG(12:0/12:0/18:1) 0.065 28.873 22.52 766.6905 2.10 TG(44:1)* 0.138 5.134 22.94 768.7067 1.26 TG(44:0)* 0.189 7.61

5 22.26 726.6601 1.67 TG(41:0)* 0.007 8.506 21.96 712.6437 0.69 TG(40:0)* 0.093 7.497 21.36 736.6438 0.89 TG(42:2)* 0.029 7.738 21.16 684.6123 0.69 TG(38:0)* 0.062 11.50

/ /9 22.56 792.7061 0.36 TG(46:2) TG(16:1/14:0/16:1) 0.273 6.0210 22.95 794.7220 0.74 TG(46:1) TG(16:0/14:0/16:1) 0.817 2.7311 23.32 796.7384 1.71 TG(46:0) TG(16:0/14:0/16:0) 0.273 14.4112 22.62 818.7216 0.22 TG(48:3) TG(16:1/14:0/18:2) 0.373 7.1313 22.95 818.7229 1.79 TG(48:3)^ 0.065 10.7814 22.97 820.7372 0.21 TG(48:2) TG(16:0/16:1/16:1) 3.304 1.8115 23.32 822.7532 0.57 TG(48:1) TG(16:0/16:0/16:1) 3.037 6.6816 23.68 824.7693 1.18 TG(48:0) TG(16:0/16:0/16:0) 0.507 27.79

Our General pro86 total co17 23.15 834.7535 0.86 TG (49:1) TG(15:0/18:1/16:1) 0.441 4.00

18 23.50 836.7691 0.84 TG (49:2) TG(15:0/18:1/16:0) 0.501 4.9519 22.25 840.7067 1.04 TG(50:6) TG(18:3/14:0/18:3) 0.012 5.5320 22.48 842.7223 1.05 TG(50:5) TG(18:2/14:0/18:3) 0.065 5.7221 22.68 844.7372 0.21 TG(50:4) TG(16:1/16:2/18:1) 0.513 8.2022 23.01 846.7524 ‐0.40 TG(50:3) TG(16:0/16:1/18:2) 4.278 2.6223 23.32 848.7681 ‐0.26 TG(50:2) TG(16:1/16:0/18:1) 11.622 4.1424 23.65 850.7843 0.23 TG(50:1) TG(16:0/16:0/18:1) 6.431 6.23

86 total co81 unique

T t d24 23.65 850.7843 0.23 TG(50:1) TG(16:0/16:0/18:1) 6.431 6.2325 24.02 852.8005 0.82 TG(50:0) TG(16:0/16:0/18:0) 0.270 43.1526 22.90 858.7536 0.98 TG(51:4) TG(15:0/18:2/18:2) 0.090 5.10

27 23.19 860.7688 0.56 TG(51:3)^ 0.427 5.0628 23.50 862.7840 ‐0.04 TG(51:2) TG(15:0/18:1/18:1) 1.106 6.3029 22.28 866.7221 0.78 TG(52:7) TG(20:4/14:0/18:3) 0.014 6.1230 22.59 868.7374 0.38 TG(52:6) TG(16:1/16:1/20:4) 0.103 7.2531 22.92 870.7524 ‐0.42 TG(52:5) TG(18:1/14:0/20:4) 0.657 8.2032 23 08 872 7679 0 55 TG(52 4) TG(18 1/16 0/18 3) 4 223 3 56

Targeted m18 compounds/u

32 23.08 872.7679 ‐0.55 TG(52:4) TG(18:1/16:0/18:3) 4.223 3.5633 23.35 874.7831 ‐1.14 TG(52:3) TG(18:1/16:0/18:2) 11.400 2.7834 24.02 874.7851 1.15 TG(52:3)^ 0.164 16.2635 23.65 876.7991 ‐0.78 TG(52:2) TG(18:1/16:0/18:1) 18.753 2.8436 25.46 876.8008 1.13 TG(52:2)^ 0.025 20.5937 23.99 878.8150 ‐0.45 TG(52:1) TG(16:0/16:0/20:1) 2.204 5.9338 22.34 892.7376 0.61 TG(54:8) TG(18:3/18:2/18:3) 0.018 5.2439 22.73 894.7524 ‐0.35 TG(54:7) TG(18:2/18:2/18:3) 0.190 8.21

* Quehenberger, O. et.al. (july 2010) Lipidomics reveals aJournal of Lipid Research.

40 22.94 896.7677 ‐0.77 TG(54:6) TG(16:0/16:0/22:6) 1.058 5.6041 23.08 898.7831 ‐1.10 TG(54:5) TG(18:1/18:1/18:3) 3.395 3.5442 23.78 898.7835 ‐0.57 TG(54:5) TG(16:1/18:0/20:4) 0.303 21.3843 23.39 900.7983 ‐1.66 TG(54:4) TG(18:2/16:0/20:2) 5.300 2.15

RT MZ New Error TG (C:DB) ID%

composition CV

(n=18)44 24.02 900.7989 ‐1.00 TG(54:4) TG(16:0/18:0/20:4) 0.632 20.5445 23 65 902 8137 1 80 TG(54:3) TG(18:1/16:0/20:2) 6 319 1 38

Rat Serum45 23.65 902.8137 ‐1.80 TG(54:3) TG(18:1/16:0/20:2) 6.319 1.3846 23.99 904.8300 ‐1.19 TG(54:2) TG(16:0/18:2/20:0) 2.780 9.5247 24.33 906.8464 ‐0.28 TG(54:1) TG(16:0/18:0/20:1) 0.249 21.6348 22.40 918.7531 0.33 TG (56:9)^ 0.021 5.2349 22.79 920.7677 ‐0.72 TG (56:8) TG(18:2/16:0/22:6) 0.207 9.8750 23.10 922.7832 ‐0.94 TG (56:7) TG(18:1/16:0/22:6) 0.950 4.4651 23.24 924.7987 ‐1.10 TG (56:6) TG(18:1/16:0/22:5) 1.262 4.5252 23.51 926.8141 ‐1.36 TG (56:5) TG(18:1/18:1/20:3) 1.160 7.5153 23.76 928.8303 ‐0.82 TG (56:4) TG(18:1/18:1/20:2) 0.635 9.9154 23.96 930.8452 ‐1.56 TG (56:3) TG(16:1/20:1/20:1) 0.774 14.8755 24.31 932.8613 ‐1.12 TG (56:2) TG(16:0/20:1/20:1) 0.227 25.1356 24.71 934.8782 0.17 TG (56:1) TG(18:0/18:0/20:1) 0.063 21.1357 22.51 944.7683 ‐0.10 TG(58:10) TG(18:2/20:4/20:4) 0.029 6.6058 22.81 946.7834 ‐0.70 TG(58:9) TG(18:2/18:1/22:6) 0.101 10.0359 23.11 948.7992 ‐0.61 TG(58:8) TG(18:1/18:1/22:6) 0.266 6.2560 23.35 950.8150 ‐0.41 TG(58:7) TG(18:1/18:1/22:5) 0.239 4.22

ofiling method:ompounds60 23.35 950.8150 0.41 TG(58:7) TG(18:1/18:1/22:5) 0.239 4.22

61 23.54 952.8304 ‐0.73 TG(58:6)^ 0.191 9.2262 23.77 954.8466 ‐0.11 TG(58:5)^ 0.110 14.8063 23.99 956.8620 ‐0.30 TG(58:4) TG(18:2/20:1/20:1) 0.091 14.4164 24.31 958.8768 ‐1.31 TG(58:3) TG(18:2/20:0/20:1) 0.131 23.0765 24.64 960.8930 ‐0.59 TG(58:2) TG(18:1/20:0/20:1) 0.108 14.1366 25.08 962.9096 0.33 TG(58:1) TG(18:1/20:0/20:0) 0.038 20.7867 22.35 968.7687 0.40 TG (60:12)^ 0.009 5.4368 22 67 970 7840 0 10 TG (60 11)^ 0 018 9 27

ompounds e masses

th d *68 22.67 970.7840 ‐0.10 TG (60:11)^ 0.018 9.2769 22.95 972.7992 ‐0.55 TG (60:10)^ 0.033 6.2870 23.12 974.8146 ‐0.79 TG (60:9)^ 0.039 8.1471 23.42 976.8299 ‐1.20 TG(60:8) TG(20:0/20:4/20:4) 0.023 10.4872 24.30 980.8125 0.14 TG(60:6) TG(20:1/20:1/20:4) 0.007 6.7773 24.02 982.8783 0.36 TG(60:5) TG(20:0/20:1/20:4) 0.031 13.4174 24.31 984.8928 ‐0.78 TG(60:4) TG(20:0/20:0/20:4) 0.058 23.8375 24.64 986.9082 ‐1.03 TG(60:3) TG(20:1/20:1/20:1) 0.087 17.13

method:*unique masses

76 25.01 988.9247 ‐0.15 TG(60:2) TG(20:0/20:1/20:1) 0.063 13.9377 25.49 990.9413 0.79 TG(60:1) TG(20:0/20:0/20:1) 0.014 24.7778 22.50 994.7840 ‐0.02 TG(62:13)^ 0.004 8.3379 23.06 998.8167 1.37 TG(62:11) TG(22:5/18:1/22:5) 0.003 20.9280 24.20 1008.8941 0.54 TG(62:6)* 0.008 18.3981 24.56 1010.9097 0.44 TG(62:5)* 0.016 19.3382 24.98 1014.9404 ‐0.12 TG(62:3)* 0.033 20.2283 25 23 1002 9411 0 59 TG(61:2)* 0 009 15 59

a remarkable diversity of lipids in human plasma,

83 25.23 1002.9411 0.59 TG(61:2) 0.009 15.5984 25.41 1016.9567 0.52 TG(62:2)* 0.019 18.8185 25.35 1042.9726 0.69 TG(64:3)* 0.009 19.3286 25.85 1044.9886 1.10 TG(64:2)* 0.006 22.41

*= lipid maps glycerolipid virtual database exact mass^ = HMDB exact mass

ResResResResIn progIn progIn progIn prog

ultsultsultsultsgressgressgress…gress…

Shared Marrkers -- Fats


if i tif inter


t drested

Diet InteractAddition an

tion Markersd Synergy?

MitochondMitochonddrial Lipidsdrial Lipids

Bird SS, Marur VR, SniatKristal BS. Lipidomics proLC-MS and high-energy cfragmentation: focus on cmitochondrial cardiolipinsmonolysocardiolipins.

Anal Chem. 2011;83;

PubMed PMID: 2119269PubMed Central PMCID:

tynski MJ, Greenberg HK, ofiling by high-resolution collisional dissociation characterization of s and

3(3):940-9.( )

6; ; PMC3031668.

Cardiolipin and Mitochondrion inner membrane

20% of all phospholipids

Cardiolipin function in mitochondriapProton trapMitochondria structureMitochondria enzymatic activities

Mitochondria dysfunctionConcentration decreasesAcyl chain composition changesOxidation

MitochondrionMitochondrion

MitochondriaCardiolipinCardiolipin

LC-MS Se• TIC mitochondria pool

– Positive ion mode– Full scan MS only

PC, PE, PGSL

PC, PE, PGSLFull scan MS only

Lyso-PCLyso-PC

RT: 0.00 - 30.01 SM: 7B

90

95

10014.94

13.31

SLSL

yLyso-PELyso-PA

yLyso-PELyso-PA

65

70

75

80

85

FA and STFA and ST

40

45

50

55

60

Rel

ative

Abu

ndan

ce

7.0112.86

1.64 2.16

15

20

25

30

35

402.32

10.19

12 18

0 2 4 6 8 10 12 14Time (m

5

10

15 12.18

3.22 5.11 7.46 8.81

eparations

G and PALG and PAL4 NL:

2.02E8TIC MS POOL_5

L L

TGTG

CLCL20.78

16.54

22.08

16 18 20 22 24 26 28 30min)

24.21

23.54 24.6619.7618.26 25.61 26.83

LC-MS Se• TIC mitochondria pool

– Negative ion mode– Full scan MS only

RT: 0.00 - 30.01 SM: 7B

90

95

10013.52

15 1

Full scan MS onlyPC, PE, PG, PA,

SL PC, PE, PG, PA,

SL

65

70

75

80

85

90 15.1

Lyso-PCLyso-PELyso-PCLyso-PE

45

50

55

60

65

Rel

ative

Abu

ndan

ce 13.10

10.47FAFA

Lyso-PALyso-PA

20

25

30

35

40R

7.17

11.87

0 2 4 6 8 10 12 14Time (m

5

10

159.00

2.72 3.87 7.611.17 4.06

eparations

15


PS, and PIPS, and PI

1 U i t it h d i15

15.70

CLCL

1. Unique to mitochondria2. Implicated in disease states3. Difficult to assay

16 74

CLCL

monoLyso-CLmonoLyso-CL16.74

17.87 19.0220.91

22 03

16 18 20 22 24 26 28 30min)

22.03

27.0822.29 23.4625.64

29.75

CL DetSIEVE frame information (m

Database searchDatabase search Full scan exact mass

Extracted Ion ChromatogramN ti i i ti [M H]Negative ionization [M-H]-Positive ionization [M+NH4]+

HCD MS/MS fragmentationDifferential fragmentation forDifferential fragmentation for

60 eVDiacylglyceroyl phosphate fragme

100 eV100 eVMonoacylglyceroyl phosphate fragmFatty acid fragmentations

60 eVtection

m/z & RT) 100 eV

s (XIC)100 eV

(pool samples)ID confirmationID confirmation

ntations

mentations

CL IdentificatioC

T: 20.00 - 26.00 SM: 7B

50

60

70

80

90

100

ve Abundance

22.93

XIC m/z 1451.996022.93

Error 0.20 ppm

70

80

90

1000

10

20

30

40

Relativ

23.22

22.6722.93

XIC m/z 697.481422.93

20.0 20.5 21.0 21.5 22.0 22.5 23.0Time (min)

0

10

20

30

40

50

60

22.4022.18

OL_60eV_1 #2487 RT: 22.94 AV: 1 NL: 2.93E4FTMS {1 1} - p ESI Full ms [120 00-2000 00]

POOLF: FTM( )FTMS {1,1} p ESI Full ms [120.00 2000.00]

70

75

80

85

90

95

1001451.9969

1453.0006

F: FTM

7

7

8

8

9

9

101451.99691453.0006

MS Scan

30

35

40

45

50

55

60

65

1454.0037

3

3

4

4

5

5

6

6

Rel

ativ

e A

bund

ance

1454.0037

[M-H]-

1438 1440 1442 1444 1446 1448 1450 1452 1454 1456 1458 1460 1462 1464 1466 1468m/z

0

5

10

15

20

25

30

1447.9635

1449.9774 1455.0062

1456.0143 1458.00931445.9478

1

1

2

2

3

1455.0062

ons HCD 60eVm/z 697.4814CL(18:1)2(18:2)2

NL: 2.37E4m/z= 1451.9916-1452.0004 MSPOOL_60eV_1

/ 69 8

1.m/z 1451.9957

2123.30 23.58 23.81

NL: 1.23E4m/z= 697.4797-697.4839 F: FTMS {1,2} - p ESI Fullms2 [email protected] [120.00-2000.00] MS POOL_60eV_12.

23.5 24.0 24.5 25.0 25.5 26.0

23.49

L_60eV_1 #2475-2503 RT: 22.84-23.08 AV: 14 NL: 8.16E3MS {1 2} - p ESI Full ms2 1000 00@hcd60 00 [120 00-2000 00]MS {1,2} p ESI Full ms2 [email protected] [120.00 2000.00]

0

5

0

5

0

5

0697.4821

HCD Scan

697.4821

0

5

0

5

0

5

0

5

698.4855698.4855

HCD Scan[M-H]-

690 691 692 693 694 695 696 697 698 699 700 701 702 703 704m/z

0

5

0

5

0

5

0

695.4666

699.4954

696.4700700.5026

690.8674 702.5111701.5027693.1261

699.8045

699.4954

CL IdentificationsT: 20.00 - 26.00 SM: 7B

20

40

60

80

100 22.91

XIC m/z 1451.996022.93 C

0

20

40

60

80

100

Relative Abundance

02322.27

22.6322.37

22.87

2321.04 21.6521.4220.7220.3723

XIC m/z 279.2324 22.93

20.0 20.5 21.0 21.5 22.0 22.5 23.0Time (min)

0

20

40

60

80

1002322.89

22.63

21.8321.3521.0220.43 20.7220.22

POOLF: FTM

OL_100eV_2 #2483 RT: 22.89 AV: 1 NL: 2.85E4FTMS {1 1} - p ESI Full ms [120 00-2000 00]

XIC m/z 281.248122.93

1451 9969 ( ) F: FTM

7

7

8

8

9

9

10

FTMS {1,1} p ESI Full ms [120.00 2000.00]

70

75

80

85

90

95

1001451.9973

1453.00071453.0006

MS Scan

1451.9969

3

3

4

4

5

5

6

6

Rel

ativ

e A

bund

ance

30

35

40

45

50

55

60

65

1454.00421454.0037

[M-H]-

1

1

2

2

3

1440 1442 1444 1446 1448 1450 1452 1454 1456 1458 1460 1462 1464 1466 1468m/z

0

5

10

15

20

25

30

1448.9674

1449.9756

1455.0072

1458.00591456.0094

1445.9518

1455.0062

s HCD 100eVNL: 2.38E4m/z= 1451.9916-1452.0004 F: FTMS {1,1} - p ESI Full ms[120.00-2000.00] MS POOL_100eV_2

CL(18:1/18:2/18:1/18:2)

3.28 23.65

3.31 23.61 23.87 24.5324.18 24.70 24.98 25.22 25.683 40

NL: 8.12E4m/z= 279.2316-279.2332 F: FTMS {1,2} - p ESI Full ms2 [email protected][120.00-2000.00] MS POOL_100eV_2

NL: 3 13E4

m/z 281.2481

23.5 24.0 24.5 25.0 25.5 26.0

3.40

23.77 24.05 24.35 24.62 24.77 25.23 25.64

NL: 3.13E4m/z= 281.2473-281.2489 F: FTMS {1,2} - p ESI Full ms2 [email protected][120.00-2000.00] MS POOL_100eV_2

L_100eV_2 #2470-2496 RT: 22.77-23.01 AV: 14 NL: 2.85E4MS {1 2} - p ESI Full ms2 1000 00@hcd100 00 [120 00-2000 00]

m/z 279.2324

279 2330MS {1,2} p ESI Full ms2 [email protected] [120.00 2000.00]

0

5

0

5

0

5

0279.2330

281.2486281.2486

HCD Scan

279.2330

0

5

0

5

0

5

0

5 HCD Scan[M-H]-

260 262 264 266 268 270 272 274 276 278 280 282 284 286 288 290 292 294 296 298 300m/z

0

5

0

5

0

5

0

282.2520

297.0472265.9509 283.2644 290.9492 298.0463274.9751 294.9537269.2484 277.2172 288.9365285.9445262.9377 273.3270

282.2520280.2402

Rat Liver MitochondMZ Error (ppm) CL Identification

1 1343.9033 ‐0.47 CL (14:0)(16:1)(16:1)(18:2)2 1517.9498 ‐0.67 CL (18:2)(18:3)(20:4)(22:6)3 1523.9979 0.05 CL (18:1)(18:2)(20:3)(22:6)4 1454.0137 0.15 CL (18:1)(18:1)(18:1)(18:2)5 1427.9995 1.16 CL (16:0)(18:1)(18:1)(18:2)6 1521.9832 0.59 CL (18:2)(18:2)(20:3)(22:6)7 1371.9351 ‐0.14 CL (14:0)(16:0)(18:2)(18:2)8 1519.9663 ‐0.09 CL (18:2)(18:2)(20:4)(22:6)9 1369.9203 0.46 CL (14:0)(16:1)(18:2)(18:2)( )( )( )( )10 1399.9669 0.26 CL (16:0)(16:1)(18:1)(18:2)11 1478.0125 ‐0.68 CL (18:1)(18:2)(18:2)(20:2)12 1495.9685 1.37 CL (18:2)(18:2)(18:2)(22:6)13 1456.0300 0.60 CL (18:1)(18:1)(18:1)(18:1)14 1499.9957 ‐1.42 CL (18:1)(18:1)(18:2)(22:6)15 1395 9351 ‐0 14 CL (14:0)(16:0)(18:2)(20:4)15 1395.9351 ‐0.14 CL (14:0)(16:0)(18:2)(20:4)16 1497.9828 0.36 CL (18:2)18:2)(20:3)(20:4)17 1469.9496 ‐0.86 CL (16:1)(18:2)(18:2)(22:6)18 1397.9503 ‐0.45 CL(16:1)(16:1)(18:1)(18:2)19 1475.9974 ‐0.28 CL (18:2)(18:2)(18:2)(20:2)20 1425.9827 0.29 CL (16:1)(18:1)(18:1)(18:2)

( )( )( )( )21 1445.9490 ‐1.30 CL (18:2)(18:2)(18:2)(18:3)22 1451.9984 0.39 CL (18:1)(18:1)(18:2)(18:2)23 1421.9526 1.25 CL(18:2)(18:2)(18:2)(16:1)24 1473.9819 ‐0.22 CL (18:2)(18:2)(18:2)(20:3)25 1471.9646 ‐1.26 CL (16:0)(18:2)(20:4)(20:4)26 1423.9673 0.94 CL(18:2)(18:2)(18:1)(16:1)27 1447.9674 0.66 CL (18:2)(18:2)(18:2)(18:2)28 1449.9816 ‐0.47 CL (18:2)(18:2)(18:2)(18:1)

rial Cardiolipins% Total Composition

CV (n=17) before correction

CV (n=17) after correction

0.3 20.9 7.90.5 24.2 9.40.9 15.4 9.81.0 18.6 11.51.0 19.6 9.41.1 17.0 12.11.1 18.7 4.71.1 16.8 3.11.1 19.3 4.31.7 18.1 5.72.3 17.6 6.62.5 16.2 7.32.8 21.8 15.53.1 17.9 7.43 3 18 7 3 23.3 18.7 3.23.8 17.4 2.93.9 21.3 8.03.9 18.3 2.64.0 17.5 8.34.5 18.4 4.15.3 21.7 6.65.5 19.0 4.66.2 17.5 2.66.8 17.5 2.87.0 19.9 4.27.9 19.3 3.38.0 16.9 4.29.5 18.0 4.3

MZ Error (ppm) CL Identification

1 1343.9033 ‐0.47 CL (14:0)(16:1)(16:1)(18:2)2 1517.9498 ‐0.67 CL (18:2)(18:3)(20:4)(22:6)3 1523.9979 0.05 CL (18:1)(18:2)(20:3)(22:6)4 1454.0137 0.15 CL (18:1)(18:1)(18:1)(18:2)5 1427.9995 1.16 CL (16:0)(18:1)(18:1)(18:2)6 1521.9832 0.59 CL (18:2)(18:2)(20:3)(22:6)7 1371.9351 ‐0.14 CL (14:0)(16:0)(18:2)(18:2)8 1519.9663 ‐0.09 CL (18:2)(18:2)(20:4)(22:6)9 1369.9203 0.46 CL (14:0)(16:1)(18:2)(18:2)( )( )( )( )10 1399.9669 0.26 CL (16:0)(16:1)(18:1)(18:2)11 1478.0125 ‐0.68 CL (18:1)(18:2)(18:2)(20:2)12 1495.9685 1.37 CL (18:2)(18:2)(18:2)(22:6)13 1456.0300 0.60 CL (18:1)(18:1)(18:1)(18:1)14 1499.9957 ‐1.42 CL (18:1)(18:1)(18:2)(22:6)15 1395 9351 ‐0 14 CL (14:0)(16:0)(18:2)(20:4)

Median raw ~13% is in

<5% on MS/da15 1395.9351 ‐0.14 CL (14:0)(16:0)(18:2)(20:4)16 1497.9828 0.36 CL (18:2)18:2)(20:3)(20:4)17 1469.9496 ‐0.86 CL (16:1)(18:2)(18:2)(22:6)18 1397.9503 ‐0.45 CL(16:1)(16:1)(18:1)(18:2)19 1475.9974 ‐0.28 CL (18:2)(18:2)(18:2)(20:2)20 1425.9827 0.29 CL (16:1)(18:1)(18:1)(18:2)

( )( )( )( )

<5% on MS/da

Mass error <1.5 21 1445.9490 ‐1.30 CL (18:2)(18:2)(18:2)(18:3)22 1451.9984 0.39 CL (18:1)(18:1)(18:2)(18:2)23 1421.9526 1.25 CL(18:2)(18:2)(18:2)(16:1)24 1473.9819 ‐0.22 CL (18:2)(18:2)(18:2)(20:3)25 1471.9646 ‐1.26 CL (16:0)(18:2)(20:4)(20:4)26 1423.9673 0.94 CL(18:2)(18:2)(18:1)(16:1)

corre

More cardiolipins th27 1447.9674 0.66 CL (18:2)(18:2)(18:2)(18:2)28 1449.9816 ‐0.47 CL (18:2)(18:2)(18:2)(18:1)in targeted

% Total CompositionCV (n=17)

before correctionCV (n=17)

after correction

0.3 20.9 7.90.5 24.2 9.40.9 15.4 9.81.0 18.6 11.51.0 19.6 9.41.1 17.0 12.11.1 18.7 4.71.1 16.8 3.11.1 19.3 4.31.7 18.1 5.72.3 17.6 6.62.5 16.2 7.32.8 21.8 15.53.1 17.9 7.43 3 18 7 3 2

CV is ~18% extraction, ata reduction3.3 18.7 3.2

3.8 17.4 2.93.9 21.3 8.03.9 18.3 2.64.0 17.5 8.34.5 18.4 4.1

ata reduction

ppm with post-ti 5.3 21.7 6.6

5.5 19.0 4.66.2 17.5 2.66.8 17.5 2.87.0 19.9 4.27.9 19.3 3.3

ection

han previously seen 8.0 16.9 4.29.5 18.0 4.3d methods

Cardiolipin D

Monolysocardiolipin (MLCLPerceived marker of oxidativPerceived marker of oxidativmitochondria

Rat liver mitochondria sampMLCL(18:2)3( )

m/z 1185.7348Degradation of CL(18:2)4

egradation

L)ve stress in

MonolysocardiolipinMonolysocardiolipin

ve stress in

les

RT: 15.53 - 19.04 SM: 7B

10017.12

MLCL (18:2)3

30

40

50

60

70

80

90

100

Relative Abundance

XIC m/z 1185.7348Error 2.11 ppm

60

70

80

90

1000

10

20

16.80

17.07

17 00

XIC m/z 695.4652E 1 87

16.0 16.5 17.0 17.Time (min)

0

10

20

30

40

50 17.00

POOL_60eV_1 #1857 RT: 17.12 AV: 1 NL: 2.33E3T: FTMS {1,1} - p ESI Full ms [120.00-2000.00]

POF: F

1185 7373

Error 1.87 ppm

T: FTMS {1,1} p ESI Full ms [120.00 2000.00]

65

70

75

80

85

90

95

1001185.7373

1186.7375

1185.7373

1186.7375

25

30

35

40

45

50

55

60

Rel

ativ

e A

bund

ance

1187.7423

Rel

ativ

e A

bund

ance

1187.7423

1182 1183 1184 1185 1186 1187 1188 1189 1190 1191m/z

0

5

10

15

201188.7328

1188.7328

NL: 2.51E3

3 at 60 eV m/z 695.4652

m/z= 1185.7312-1185.7384 F: FTMS {1,1} - p ESI Full ms [120.00-2000.00] MS POOL_60eV_1

17.65

NL: 2.95E2m/z= 695.4631-695.4673 F: FTMS {1,2} - p ESI Full ms2 [email protected] [120.00-2000.00] MS POOL_60eV_1

5 18.0 18.5 19.0

18.14

OOL_60eV_1 #1839-1869 RT: 16.96-17.22 AV: 15 NL: 1.70E2FTMS {1,2} - p ESI Full ms2 [email protected] [120.00-2000.00]

100695.4665

65

70

75

80

85

90

95

100

695.4665

25

30

35

40

45

50

55

60

694.0 694.5 695.0 695.5 696.0 696.5 697.0 697.5 698.0m/z

0

5

10

15

20 697.0258

696.4709694.6697

696.4709

MLCL (18:2)3RT: 16.22 - 17.79 SM: 7B

60

80

100

Abu

ndan

ce

17.09

XIC m/z 1185.7348Error 1.26 ppm

80

1000

20

40

Relative A

16.74

17.08

pp

XIC m/z 279.2324

POOL 100eV 1 #1842-1868 RT: 16.98-17.20 AV: 13 NL: 1.98E316.4 16.6 16.8 17.00

20

40

60 16.75 16.7916.26 16.3716.42

16.53

Error 1.79 ppm

_ _T: FTMS {1,1} - p ESI Full ms [120.00-2000.00]

70

80

90

100

e

1185.7363

1186 3941186.7394

1185.7363Time (min)

20

30

40

50

60

Rel

ativ

e A

bund

ance 1186.7394

1187 74161187.7416

1185.0 1185.5 1186.0 1186.5 1187.0 1187.5 1188.0 1188.5 1189.0m/z

0

10

20 1187.7416

1188.5203

at 100 eVNL: 2.60E3m/z= 1185.7312-1185.7384 F: FTMS {1,1} - p ESI Full ms [120.00-2000.00] MS POOL_100eV_1

17.29

NL: 1.94E3m/z= 279.2316-279.2332 F: FTMS {1,2} - p ESI Full ms2 [email protected] [120 00-2000 00] MS

m/z 279.2324

POOL 100eV 1 #1841-1867 RT: 16.97-17.19 AV: 13 NL: 1.44E317.2 17.4 17.6

17.43

17.25 17.6017.77

[120.00 2000.00] MS POOL_100eV_1

POOL_100eV_1 #1841 1867 RT: 16.97 17.19 AV: 13 NL: 1.44E3F: FTMS {1,2} - p ESI Full ms2 [email protected] [120.00-2000.00]

70

80

90

100

e

279.2329

279.2329

30

40

50

60

Rel

ativ

e A

bund

ance

279.0 279.2 279.4 279.6 279.8 280.0 280.2 280.4 280.6 280.8m/z

0

10

20

280.2364279.9273

279.9900279.7630

280.2364

RT: 0.00 - 30.01 SM: 7B

50

60

70

80

90

100

Abun

danc

e

13.52

15.15

15.70

13.10

Mitochondria TIC

Card

0 2 4 6 8 10 12 14 16 18 20 2Time (min)

0

10

20

30

40

50

Relative A 10.47

16.747.17

11.8717.87 19.02 20.91

9.002.72 3.87 7.611.17 4.06

Card

Time (min)

RT: 20.00 - 26.00 SM: 7B

60

80

100Ab

unda

nce

22.92

Cardiolipin m/z 1454.996022.9

60 eV

40

60

80

1000

20

40

Rel

ativ

e A

23.3722.5222.26 23.6322.64

22.9122.9

m/z 697.4814

100 eVm/z 281.2481

100 eVm/z 279.2324

20.0 20.5 21.0 21.5 22.0 22.5 23.0 23.5 24.0 24.5Time (min)

0

20

40

23.2324.06

RT: 20.00 - 26.00 SM: 7B

60

80

100

Abu

ndan

ce

22.60

22.8622.32 22.9

60

80

1000

20

40

Rel

ativ

e A

23.1421.80 23.65 24.0420.95 24.520.75

23.3622.86

22.60

22.9

20.0 20.5 21.0 21.5 22.0 22.5 23.0 23.5 24.0 24.5Time (min)

0

20

40

23.78 24.0420.64 20.9220.32 21.29 21.66 24


iolipins

22 24 26 28 30

22.0327.0822.29 23.46

29.75

iolipins

NL: 1.50E4m/z= 1451.9916-1452.0004 F: FTMS {1,1} - p ESI Full ms [120.00-2000.00] MS POOL_60eV_1

XIC m/z 1451.9960Full Scan MSCL (18:1)2(18:2)2

In profiling…

Sensitive to 0 0015% ofNL: 1.24E4m/z= 697.4793-697.4835 F: FTMS {1,2} - p ESI Full ms2 [email protected] [120.00-2000.00] MS POOL_60eV_1

2 2

XIC m/z 697.481460 eV HCD ScanCL (18:1)(18:2)

Sensitive to 0.0015% of total lipid

Median 5% CV on MS/data25.0 25.5 26.0NL: 4.14E4

m/z= 279.2310-279.2338 F: FTMS {1,2} - p ESI Full ms2 [email protected] [120.00-2000.00] MS POOL_100eV_2

XIC m/z 279.2324100 eV HC ScanFA (18:2)

Median 5% CV on MS/data reduction

(at 0.006% of lipids)

52 25.08 25.59NL: 2.90E4m/z= 281.2467-281.2495 F: FTMS {1,2} - p ESI Full ms2 [email protected] [120.00-2000.00] MS POOL_100eV_2

XIC m/z 281.2481100 eV HC ScanFA (18:1)

0.0015% of total lipid

Mass error <1.5 ppm

More cardiolipins and TGs

25.0 25.5 26.0

4.52 25.08 25.30

FA (18:1)than previously seen in

targeted methods

Lipid ClassUnique Nu

LipidGlycerophospholipids (GP)

Phosphocholine (PC) 10plasmalogenphosphocholine (plsPC) 5lysoPhosphocholine (LysoPC) 19

Phosphoethanolamine (PE) 62plasmalogenphosphoethanolamine (plsPE) 6lysoPhosphoethanolamine (LysoPE) 9lysoPhosphoethanolamine (LysoPE) 9

Phosphoserine (PS) 18Phosphoinositol (PI) 11Phosphoglycerol (PG) 31Cardiolipin (CL) 26

monolysocardiolipin (MLCL) 2

Fatty Acyls (FA)Branched Fatty acid 1Acylamide 1Octadecanoids 2Acylcarnitines (AcCar) 3y ( )

Sphingolipids (SL)Sphingomyelins (SM) 6Ceramides (Cer) 21Gangliosides (Gan) 4

Glycerolipids (GL)Monoacylglycerol (MG) 4Diacylglycerol (DG) 4Triacylglycerol (TG) 43

Prenol Lipids (PL)coenzyme‐Q (CoQ) 3

**Defined as having a unique mass and retention time pair that rboth ionization modes are only counted once.

umber of s** ‐ Ionization + Ionization

03 [M+FormAcid]‐ [M+H]+5 [M+FormAcid]‐ [M+H]+9 [M+FormAcid]‐ [M+H]+2 [M‐H]‐ [M+H]+6 [M‐H]‐ [M+H]+9 [M‐H]‐ [M+H]+9 [M H] [M+H]+8 [M‐H]‐1 [M+NH4]+1 [M‐H]‐ [M+H]+ / [M+NH4]+6 [M‐H]‐ [M+NH4]+2 [M‐H]‐ [M+NH4]+

1 [M+NH4]+1 [M‐H]‐2 [M+H]+ / [M+NH4]+3 [M+H]+[ ]

6 [M+FormAcid]‐ [M+H]+1 [M+FormAcid]‐ [M+H]+4 [M‐H]‐/[M‐H20‐H]‐ [M+NH4]+

4 [M+NH4]+4 [M+NH4]+3 [M+NH4]+

3 [M+H]+ / [M+NH4]+

represents a distinct species. Those species that are observed in

Sphingolipids (SL)IonizaMo

Ceramides (Cer)Cer(d18:0/14:1) or Cer(d18:1:14:0) ‐Cer(d18:0/16:0) ‐Cer(d18:0/16:0) ‐Cer(d18:0/16:1) or Cer(d18:1/16:0) ‐/+Cer(d18:0/18:1) or Cer(d18:1/18:0) ‐Cer(d18:0/20:1) or Cer(d18:1/20:0) ‐Cer(d18:0/22:0) or Cer(d18:1/22:1) ‐Cer(d18:0/22:1) or Cer(18:1/22:0) ‐/+C (d18 0/22 2) C (d18 1/22 1)Cer(d18:0/22:2) or Cer(d18:1/22:1) ‐Cer(d18:0/23:0) ‐/+Cer(d18:0/23:1) or Cer(d18:1/23:0) ‐Cer(d18:0/24:0) ‐/+Cer(d18:0/24:1) or Cer(d18:1/24:0) ‐/+Cer(d18:0/24:2) or Cer(d18:1/24:1) ‐Cer(d18:0/25:1) or Cer(d18:1/25:0) ‐/+Cer(d18:0/26:0) ‐Cer(d18:0/26:1) or Cer(d18:1/26:0) ‐/+Cer(d18:0/26:2) or Cer(d18:1/26:1) ‐/+GlcCer(d18:0/16:1) or GlcCer(d18:1/16:0) ‐GlcCer(d18:0/24:1) or GlcCer(d18:1/24:0) ‐/+( / ) ( / ) /GlcCer(d18:0/24:2) or GlcCer(d18:1/24:1) ‐GlcCer(d18:0/25:1) or GlcCer(d18:1/25:0) ‐

Sphingomyelin (SM)SM(d18:0/24:2) or SM(d18:1/24:1) ‐SM(d18:0/18:1) or SM(d18:1/18:0) ‐SM(d18:0/18:1) or SM(d18:1/18:0) ‐SM(d18:0/22:1) or SM(d18:1/22:0) ‐SM(d18:0/22:2) or SM(d18:1/22:1) +SM(d18:0/23:1) or SM(d18:1/23:0) ‐SM(d18:0/24:1) or SM(d18:1/24:0) ‐/+

G li id (G )Gangliosides (Gan)Gan(d18:0/18:2) or Gan(d18:1/18:1) ‐Gan(d18:0/24:1) or Gan(d18:1/24:0) ‐Gan(d18:0/26:0) ‐Gan(d18:0/26:1) or Gan(d18:1/26:0) +

ation de m/z

Error (ppm)

Intensity (n=8)

CV (n=8)

554.4800 1.77 218.08 7.51584 5276 2 72 389 73 5 09584.5276 2.72 389.73 5.09

+ 582.5109 1.07 13011.92 4.17610.5428 2.04 896.24 6.96638.5739 1.59 565.03 8.13668.6214 2.24 493.43 17.26

+ 666.6050 1.26 10829.24 5.10664 5903 2 76 1571 52 7 34664.5903 2.76 1571.52 7.34

+ 682.6370 2.23 406.10 16.99680.6205 0.86 14505.47 6.29

+ 696.6528 2.40 1782.43 7.34+ 694.6365 1.49 77735.14 6.12

692.6205 0.84 31587.01 5.28+ 708.6527 2.27 12455.20 4.22

724.6841 2.18 478.34 32.65+ 722.6682 2.09 2093.79 6.65+ 720.6525 1.90 2185.09 6.47

700.5724 0.23 5487.51 7.04+ 856.6898 1.66 9681.37 5.97

854.6752 2.96 1372.72 4.98870.7060 2.29 497.52 6.24

857.6774 2.48 5909.13 5.24775 5988 2 13 528 09 6 70775.5988 2.13 528.09 6.70831.6624 3.26 3535.84 4.52787.6673 ‐1.88 33719.26 5.97845.6770 2.01 3103.26 5.95

+ 859.6932 2.65 14886.09 6.70

1399.8468 3.41 5175.93 7.461511.9214 0.45 1001.41 4.461541.9683 0.36 998.71 7.501539.9506 0.87 1610.44 8.12

Glycerolipids (GLs)Retention Time (min) [M+

Triacylglycerols (TG)TG(42:0) 23.14 74TG(44:1) 23.18 76TG(44 0) 23 54 76TG(44:0) 23.54 76TG(16:1/14:0/16:1) 23.24 79TG(16:0/14:0/16:1) 23.58 79TG(16:0/14:0/16:0) 23.94 79TG(16:1/14:0/18:2) 23.30 81TG(16:0/16:1/16:1) 23.55 82TG(16:0/16:0/16:1) 23.94 82

( / / )TG(16:0/16:0/16:0) 24.34 82TG(15:0/18:1/16:1) 23.79 83TG(15:0/18:1/16:0) 24.12 83TG(16:1/16:2/18:1) 23.45 84TG(16:0/16:1/18:2) 23.58 84TG(16:1/16:0/18:1) 23.90 84TG(16:0/16:0/18:1) 24.32 85

/ /TG(16:0/16:0/18:0) 24.76 85TG(51:3) 23.79 86TG(15:0/18:1/18:1) 24.12 86TG(18:1/14:0/20:4) 23.44 87TG(18:1/16:0/18:3) 23.63 87TG(18:1/16:0/18:2) 23.94 87TG(18:1/16:0/18:1) 24.30 87TG(16:0/16:0/20:1) 24.73 87TG(18:2/18:2/18:3) 22.98 89TG(16:0/16:0/22:6) 23.31 89TG(18:1/18:1/18:3) 23.82 89TG(18:2/16:0/20:2) 23.94 90TG(18:1/16:0/20:2) 24.30 90TG(16:0/18:2/20:0) 24.29 90TG(16:0/18:2/20:0) 24.80 90TG(16:0/18:0/20:1) 25.18 90TG(18:2/16:0/22:6 23.39 92TG(18:1/16:0/22:6) 23.65 92TG(18:1/16:0/22:5) 23.82 92TG(18:1/18:1/20:3) 23.82 92TG(18:1/18:1/20:2) 24.30 92TG(16:1/20:1/20:1) 24.27 93TG(18:1/18:1/20:1) 24.77 93TG(16:0/20:1/20:1) 25.15 93TG(18:0/18:0/20:1) 25.73 93TG(18:1/18:1/22:6) 23.75 94TG(18:1/20:0/20:1) 25.62 96

m/z +NH4]+

Error (ppm) Intensity (n=8)

CV (n=8)

40.6751 ‐1.50 8842.53 2.3766.6910 0.53 14431.06 1.7568 7069 0 84 21076 17 2 4368.7069 ‐0.84 21076.17 2.4392.7066 ‐1.25 18642.42 1.1094.7220 ‐1.46 46902.02 2.3296.7380 ‐0.96 54969.44 2.5118.7223 ‐1.12 12904.38 1.7220.7373 ‐1.87 66223.40 2.9922.7530 ‐1.82 129812.51 2.7324.7683 ‐2.16 82666.03 3.1234.7535 ‐1.24 36149.02 2.2636.7687 ‐1.71 53382.01 2.7144.7381 ‐0.88 7706.02 1.9446.7528 ‐2.01 44360.38 3.3348.7679 ‐2.57 221864.86 3.4050.7839 ‐2.23 223290.46 3.5552.8001 ‐1.59 28738.42 1.9060.7691 ‐1.19 13782.24 3.0862.7845 ‐1.54 35190.99 2.0870.7535 ‐1.18 15613.91 2.5972.7685 ‐1.88 48442.48 2.8174.7832 ‐2.99 163329.11 3.0476.7988 ‐3.07 420036.40 4.3278.8151 ‐2.28 68296.23 1.6094.7538 ‐0.81 9858.46 2.2996.7683 ‐2.00 41949.09 2.0398.7835 ‐2.58 92349.53 3.1500.7990 ‐2.81 89876.78 3.1402.8140 ‐3.46 163085.51 3.9204.8300 ‐3.12 72646.91 3.2704.8282 ‐5.14 62395.92 6.3006.8469 ‐1.70 24588.81 2.8020.7688 ‐1.46 4161.86 2.9822.7837 ‐2.31 7296.70 4.1624.7993 ‐2.34 17143.46 3.4726.8153 ‐1.97 15708.78 3.0928.8311 ‐1.88 16358.28 3.9430.8467 ‐1.82 14833.24 3.5730.8470 ‐1.55 16618.48 4.5532.8628 ‐1.35 14641.88 2.0334.8788 ‐1.08 12148.54 1.7148.7991 ‐2.49 4051.18 3.8260.8943 ‐0.99 8638.94 2.35

Glycerolipids (GLs)Retention Ti

(min)Monoacylglycerols (MGs)

MG(0:0/18:3) 3.73MG(0:0/20:1) 3 31MG(0:0/20:1) 3.31MG(0:0/22:1) 5.10MG(plasmalogen18:0) 2.34

Diacylglycerols (DGs)DG(36 1) 12 49DG(36:1) 12.49DG(38:1) 13.99DG(38:5) 17.21DG(40:10) 15.52

ime m/z [M+NH4]+

Error (ppm)

Intensity (n=8)

CV (n=8)

370.2947 ‐1.05 30076.64 3.63402 3573 ‐0 99 7149 69 4 37402.3573 ‐0.99 7149.69 4.37430.3884 ‐1.61 14928.54 3.46360.3466 ‐1.61 126268.17 3.93

640 5872 0 59 8454 21 4 09640.5872 0.59 8454.21 4.09668.6191 0.53 7049.42 5.74660.5557 ‐0.42 5559.73 5.26696.6491 ‐1.22 6229.87 4.47

Glycerophospholipids (PLs)Phosphocholine (PC)

PC(14:1/22:5) PC(18:1/18:1)PC(14 1/22 5) PC(18 1/18 1)PC(14:1/22:5) PC(18:1/18:1)PC(15:0/15:0) PC(18:2/16:0)PC(15:0/16:1) PC(18:2/16:1)PC(15:0/18:1) PC(18:2/18:0)PC(15:0/18:2) PC(18:2/20:4)PC(15:0/20:2) PC(18:3/14:0)PC(15:0/20:3) PC(18:3/16:0)PC(15:0/20:3) PC(18:3/16:0)PC(15:0/20:3) PC(18:3/18:4)PC(15:0/20:4) PC(18:3/22:4)PC(15:0/20:4) PC(18;1/16:0)PC(15:0/22:1) PC(20:1/18:0)PC(16:0/16:0) PC(20:2/18:0)PC(16:0/20:5) PC(20:2/18:0)PC(16:0/20:5) PC(20:2/18:0)PC(16:0/20:5) PC(20:3/18:0)PC(16:1/14:0) PC(20:3/18:0)PC(17:0/20:4) PC(20:3/18:0)PC(18:0/14:1) PC(20:4/14:0)PC(18:0/18:0) PC(20:4/14:1)PC(18:0/22:4) PC(20:4/16:0)PC(18:0/22:5) PC(20:4/16:1)PC(18:0/22:5) PC(20:4/18:0)PC(18:0/22:6) PC(20:4/18:0)PC(18:1/14:1) PC(20:4/20:4)PC(18:1/18:0) PC(20:4/20:5)

plasmalogenphosphocholine (plsPC) lysoPhosphocholine PC plasmalogen(38:4) LysoPAF(C16)PC(plasmalogen(18:3/18:0) LysoPC (16:0)PC(plasmalogen36:5) LysoPC (16:1)PCplasmalogen(34:0) lysoPC (18:0)PCplasmalogen(38:3) lysoPC (18:1)

lysoPC (18:2)y ( )lysoPC(14:0)

PC(20:5/16:0) PC(34:4) or PE(37:4) PC(42:9)PC(22 5/15 0) PC(35 1) PE(38 1) PC(44 11)PC(22:5/15:0) PC(35:1) or PE(38:1) PC(44:11)PC(22:5/15:0) PC(35:1) or PE(38:1) PC(44:12)PC(22:5/16:0) PC(35:2) or PE(38:2)PC(22:5/16:0) PC(35:3) or PE(38:3)PC(22:6/15:0) PC(36:3) PC(22:6/16:0) PC(36:3) PC(22:6/16:1) PC(36:4)PC(22:6/16:1) PC(36:4) PC(22:6/20:4) PC(38:0)

PC(32:1) or PE(35:1) PC(38:0)PC(34:0) PC(38:8)PC(34:3) PC(38:8)PC(38:7) PC(38:9)PC(38:7) PC(40:10)PC(38:7) PC(40:10)PC(40:4) PC(40:10)PC(40:6) PC(40:3)PC(40:6) PC(40:8)PC(40:7) PC(42:10)

PC (32:1) or PE (35:1) PC(42:11)PC (32:1) or PE (35:1) PC(42:7)PC (32:2) or PE (35:2) PC(42:8)PC (32:4) or PE (35:4) PC(42:8)PC (32:4) or PE (35:4) PC(42:8)PC(34:2) or PE(37:2) PC(42:9)PC(34:4) or PE(37:4) PC(42:9)

(LysoPC)lysoPC(20:0) lysoPC(18:3)lysoPC(20:3) LysoPC(22:0)LysoPC(20:4) lysoPC(4:0)lysoPC(20:5) lysoPC(o‐12:0)lysoPC(22:5) lysoPC(o‐12:0/o‐1:0) lysoPC(22:6) lysoPC(o‐12:0/o‐1:0) y ( ) y ( )

lysoPAF(C18:0)

Glycerophospholipids (PLs)Glycerophospholipids (PLs)Phosphoethanolamine (PE)

PE(14:0/20:3) PE(22:5/16:0)PE(15:0/15:0) PE(22:5/18:0)PE(16:0/16:1) PE(22:5/18:2)( / ) ( / )PE(16:0/18:0) PE(22:6/15:0)

PE(16:0/20:4) PE(22:6/16:0)PE(18:0/22:4) or PE(20:4/20:0) PE(22:6/18:0)PE(18:0/22:4) or PE(20:4/20:0) PE(22:6/18:2)PE(18:1/16:0) PE(22:6/20:0)PE(18:1/18:0) PE(22:6/22:6)PE(18:2/16:0) PE(32:0)PE(18:2/18:0) PE(32:2)PE(18:3/18:0) PE(33:1)PE(18:3/18:2) PE(34:4)PE(18:3/18:2) PE(34:4)PE(20:3/18:0) PE(34:4)PE(20:3/18:0) PE(36:0)PE(20:3/18:4) PE(36:1)PE(20:4/15:0) PE(36:3)PE(20 4/16 1) PE(40 3)PE(20:4/16:1) PE(40:3)PE(20:4/18:0) PE(40:3)PE(20:4/22:1) PE(40:6)PE(20:4/22:6) or (20:5:22:5) PE (34:1) or PC (31:1)PE(20:5/18:0) PE (34:3)PE(20:5/18:2) PE(36:2) or PC(33:2)PE(22:4/15:0) PE(36:2) or PC(33:2)PE(22:4/16:0) PE(38:8)

plasmalogenphosphoethanolamine (plsPE)PE(40:1) PE(20:4/plasmalogen18:0)PE(40:2) PE(20:4/plasmalogen18:1)PE(40:2) PE(22:4/plasmalogen16:0)( ) ( )PE(40:5) PEplasmalogen(38:6)

PE(40:8) PEplasmalogen(36:4)PE(42:4)PE(42:4)PE(42:5) lysoPhosphoethanolamine (LysoPE)PE(44:5) LysoPE(16:0) LysoPE(22:0)PE(44:6) LysoPE(18:0) LysoPE(22:5)

LysoPE(18:1) LysoPE(22:6)LysoPE(18:2) LysoPE(20:4)lysoPE(20:4)lysoPE(20:4)

)

Glycerophospholipids (PLs)Glycerophospholipids (PLs)Phosphoglycerol (PG) Ph

PG(16:0/16:0) PG(32:2) or PA(36:2) PPG(16:0/16:1) PG (34:0) PPG(16:0/20:4) PG (34:2) PPG(16:1/16:1) PG (36:0) PPG(16 1/18 2) PGP(34 2) PPG(16:1/18:2) PGP(34:2) PPG(18:0/18:1) PGP(36:0) PPG(18:0/18:2) PGP(36:1) PPG(18:0/18:3) PGP(36:1) PPG(18:1/16:0) PGP(36:2) PPG(18:1/18:1) PGP(36:3) P( / ) ( )PG(18:1/20:3) PGP(38:4) PPG(18:1/22:5) PGP(40:6) PPG(18:2/18:2) PGP(40:6) PPG(18:2/20:3) PPG(18:2/22:6) PPG(22:5/16:1) PPG(22:5/16:1) PPG(22:6/16:1) PPG(22:6/18:1) P

Cardiolipin (CL)CL (14:0)(16:1)(16:1)(18:2) CL (18:2)(18:2)(18:2)(22:6)CL (18:2)(18:3)(20:4)(22:6) CL (18:1)(18:1)(18:1)(18:1)CL (18:1)(18:2)(20:3)(22:6) CL (18:1)(18:1)(18:2)(22:6)CL (18:1)(18:1)(18:1)(18:2) CL (14:0)(16:0)(18:2)(20:4)CL (16:0)(18:1)(18:1)(18:2) CL (18:2)18:2)(20:3)(20:4)CL (18:2)(18:2)(20:3)(22:6) CL (16:1)(18:2)(18:2)(22:6)CL (14:0)(16:1)(18:1)(18:2) CL(16:1)(16:1)(18:1)(18:2)CL (14:0)(16:1)(18:1)(18:2) CL(16:1)(16:1)(18:1)(18:2)CL (18:2)(18:2)(20:4)(22:6) CL (18:2)(18:1)(18:2)(20:3)CL (14:0)(16:1)(18:2)(18:2) CL (16:1)(18:1)(18:1)(18:2)CL (16:0)(16:1)(18:1)(18:2) CL (18:2)(18:2)(18:2)(18:3)

hosphoserine (PS) Phosphoinositol (PI)PS(16:0/16:0) PI(36:2)PS(16:0/18:3) PI(36:4)PS(16:0/20:3) PI(38:3)PS(16:0/22:6) PI(38:3)PS(16 0/22 6) PI(38 4)PS(16:0/22:6) PI(38:4)PS(16:1/22:6) PI(38:4)PS(18:0/22:6) PI(38:5)PS(18:1/22:6) PI(38:5)PS(18:2/18:2) PI(40:4)PS(18:2/22:6) PI(40:5)( / ) ( )PS(18:2/22:6) or PS(20:3/20:4) PIP(38:2)PS(20:0/18:0)PS(20:3/18:1)PS(20:3/18:2)PS(20:3/18:2)PS(22:5/18:0)PS(22:5/18:0)PS(22:5/28:0)PS(22:6/18:3)

monolysocardiolipin (MLCL)CL (18:1)(18:1)(18:2)(18:2) MLCL(18:2)3CL(18:2)(18:2)(18:2)(16:1) MLCL(18:2)2(18:1)CL (18:2)(18:2)(18:2)(20:3)CL(18:2)(18:2)(18:1)(16:1)CL (18:2)(18:2)(18:2)(18:2)CL (18:2)(18:2)(18:2)(18:1)

Untargeted metUntargeted metsemi-, or very

Mit h d i l li id iMitochondrial lipidomics…Accepted Online 2/2012

thod now looksthod now looks y, targeted…

Bi d t l M t b l i…. Bird et al., Metabolomics

…many seen in plasma as well

BuBu

Functional MTargTarg

tt…

Mitochondrial ets?ets?


if i tif inter


t drested

Big Bottlleneck…


AnalyticalAnalyticalCC GChemistryChemistry

----CC

G

CoularrayCoularray + + IDs + software IDs + software

li id ili id i+ lipidomics+ lipidomics


EIData Data

EI

AnalysisAnalysis

Leverage…

Biochemical MTarg

Mitochondrial gets

Biochemical MTargeTarge

Lip

Mitochondrial etsets…

ids



Cardiolipin function in mitochondriapProton trapMitochondria structureMitochondria enzymatic activities

Mitochondria dysfunctionConcentration decreasesAcyl chain composition changesOxidation





Cardiolipin function in mitochondriapProton trapMitochondria structureMitochondria enzymatic activitiesThe Centra

Mitochondria dysfunctionConcentration decreasesAcyl chain composition changesOxidationEnergy Me


Energy Me


al Lipid in petabolismetabolism

CL– Key rCL Key r• Primarily four equivale• Essentially always dec

– Most susceptible lipid tMost susceptible lipid t

regulationregulationent chains, eg., 18:2creased in pathologyto peroxidationto peroxidation

Two stage synthesis – make…

and remodelTafazzin (Barth Syndrome)ALCAT (acyl-CoA lysocard

…

)diolipin acyltransferase)


if i tif inter


t drested

Can we look at oCan we look at oin the lipid co

Ideally somethIdeally…somethaccum

oxidative stressoxidative stress ompartment?

hing that mighthing that might mulate

Cardiolipin Degradatio

Monolysocardiolipin (MLCLPerceived marker of oxidativPerceived marker of oxidativmitochondria

Rat liver mitochondria sampMLCL(18:2)3( )

m/z 1185.7348Degradation of CL(18:2)4

on and Remodeling

L)ve stress in

MonolysocardiolipinMonolysocardiolipin

ve stress in

les

Glycerophospholipids (PLs)Glycerophospholipids (PLs)Phosphoglycerol (PG) Ph

PG(16:0/16:0) PG(32:2) or PA(36:2) PPG(16:0/16:1) PG (34:0) PPG(16:0/20:4) PG (34:2) PPG(16:1/16:1) PG (36:0) PPG(16 1/18 2) PGP(34 2) PPG(16:1/18:2) PGP(34:2) PPG(18:0/18:1) PGP(36:0) PPG(18:0/18:2) PGP(36:1) PPG(18:0/18:3) PGP(36:1) PPG(18:1/16:0) PGP(36:2) PPG(18:1/18:1) PGP(36:3) P( / ) ( )PG(18:1/20:3) PGP(38:4) PPG(18:1/22:5) PGP(40:6) PPG(18:2/18:2) PGP(40:6) PPG(18:2/20:3) PPG(18:2/22:6) PPG(22:5/16:1) PPG(22:5/16:1) PPG(22:6/16:1) PPG(22:6/18:1) P

Cardiolipin (CL)CL (14:0)(16:1)(16:1)(18:2) CL (18:2)(18:2)(18:2)(22:6)CL (18:2)(18:3)(20:4)(22:6) CL (18:1)(18:1)(18:1)(18:1)CL (18:1)(18:2)(20:3)(22:6) CL (18:1)(18:1)(18:2)(22:6)CL (18:1)(18:1)(18:1)(18:2) CL (14:0)(16:0)(18:2)(20:4)CL (16:0)(18:1)(18:1)(18:2) CL (18:2)18:2)(20:3)(20:4)CL (18:2)(18:2)(20:3)(22:6) CL (16:1)(18:2)(18:2)(22:6)CL (14:0)(16:1)(18:1)(18:2) CL(16:1)(16:1)(18:1)(18:2)CL (14:0)(16:1)(18:1)(18:2) CL(16:1)(16:1)(18:1)(18:2)CL (18:2)(18:2)(20:4)(22:6) CL (18:2)(18:1)(18:2)(20:3)CL (14:0)(16:1)(18:2)(18:2) CL (16:1)(18:1)(18:1)(18:2)CL (16:0)(16:1)(18:1)(18:2) CL (18:2)(18:2)(18:2)(18:3)

hosphoserine (PS) Phosphoinositol (PI)PS(16:0/16:0) PI(36:2)PS(16:0/18:3) PI(36:4)PS(16:0/20:3) PI(38:3)PS(16:0/22:6) PI(38:3)PS(16 0/22 6) PI(38 4)PS(16:0/22:6) PI(38:4)PS(16:1/22:6) PI(38:4)PS(18:0/22:6) PI(38:5)PS(18:1/22:6) PI(38:5)PS(18:2/18:2) PI(40:4)PS(18:2/22:6) PI(40:5)( / ) ( )PS(18:2/22:6) or PS(20:3/20:4) PIP(38:2)PS(20:0/18:0)PS(20:3/18:1)PS(20:3/18:2)PS(20:3/18:2)PS(22:5/18:0)

0.0015% of total lipid Signal based on 10k framesPS(22:5/18:0)

PS(22:5/28:0)PS(22:6/18:3)

monolysocardiolipin (MLCL)CL (18:1)(18:1)(18:2)(18:2) MLCL(18:2)3

Signal based on 10k frames

CL(18:2)(18:2)(18:2)(16:1) MLCL(18:2)2(18:1)CL (18:2)(18:2)(18:2)(20:3)CL(18:2)(18:2)(18:1)(16:1)CL (18:2)(18:2)(18:2)(18:2)CL (18:2)(18:2)(18:2)(18:1)


if i tif inter


t drested

18:1/18:1 lipids u18:1/18:1 lipids uisomerization in the pr

Ferreri, C.; Panagiotaki, M.; Chatgilg gMol Biotechnol 2007, 37, 19-

Zambonin, L.; Ferreri, C.; Cabrini, LLandi L Free Radic Biol MeLandi, L. Free Radic Biol Me

Zambonin, L.; Prata, C.; Cabrini, L.Dalla Sega, F.; Hakim, G.;LaF R di Bi l M d 2008 4Free Radic Biol Med 2008, 4

undergo Cis Transundergo Cis-Transresence of Thiyl radicals

lialoglu, C. g-25.L.; Prata, C.; Chatgilialoglu, C.;ed 2006 40 1549-1556ed, 2006, 40, 1549-1556.; Maraldi, T.; Fiorentini, D.; Vieceli

andi, L. 44 594 60144, 594-601.

Cis-TranPG (18 1/18 1) Cis

Cis-Tran– PG (18:1/18:1) – Cis

– PG (18:1/18:1) - Trans

ns Lipidsns Lipids

Cis-Trans 18:1/18:1 lipids are cchromatographically separable

18:1/18:1 lipids undergo p gin the presence

Cis-Trans isomerizationof Thiyl radicals

Cis-Trans PG 18:1/18:chromatographically sg p y

Bird, S.S.; Marur, V.R.; Stavrovskayof Cis-Trans Phospholipid Isomers p pHigh Resolution MS Detection, Ana

:1 (and PC) lipids are separable in poolp p

ya, I.G.,.; Kristal, B.S., Separation using Reversed Phase LC with g

alytical Chemistry, 2012, 84:5509-17


if i tif inter


t drested

ImplicImplic

• 1 week mass spec –

• Bypasses bottleneck

• Quadruples the actiofrom a ~$1.7M study

• Leverages all other d

cationcation

k

onable information

data…

Method DeveFecal Lipidom

Katherine Gregory and

Vera Gross and AlexanVera Gross and Alexan(Pressure Bioscienc

Vasant R. Marur

W. Allan Walker, Bruce

elopment for mics Profiling

Susan Bird, (Co-First)

der Lazarevder Lazarevces)

S Kristal

Fecal SFecal S•• NutritionNutrition•• Gut FunctionGut Function•• CancerCancer•• CancerCancer•• Neonatal/premNeonatal/prem

StudiesStudies

mature infantsmature infants

Primary Lipid (really feAnalysis Pressure vs NAnalysis Pressure vs N

eatures) Population No pressure LC MS ES+No pressure, LC-MS, ES+

Top left set of panels: The linear scale ofrelative abundance. This panel emphasisample

f lipid abundance as defined by MS zes the most abundant lipids in the

Top left set of panels: The linear scale ofrelative abundance. This panel emphasisample

f lipid abundance as defined by MS zes the most abundant lipids in the

Pressure improves yield (Qual? Quant?)y (Q Q )in MBTE

•Top right set: The log scale emphasizes t•Within these panels, lower left quadrant <•We expect that these lipids would be quan•platform used.

the overall distribution of lipids.<1000 for either the X or Y condition. ntitatively unreliable for the LC-MS

•Top right set: The log scale emphasizes t•Within these panels, lower left quadrant <•We expect that these lipids would be quan•platform used.

Pressure improves i ld (Q l? Q t?)yield (Qual? Quant?)

Esp MBTE

the overall distribution of lipids.<1000 for either the X or Y condition. ntitatively unreliable for the LC-MS

Bottom left set of panels: The overall CVshows 10,000 frames for positive ion momode. These panels emphasize the totaapproach.

V scale of SIEVE data series. This panel ode and 7,000 frames for negative ion l lipid yield based on the specific

Bottom right set of panels: The CV scaleemphasizes the "useful peaks" of lipids

e truncated at 40% CV. This panel measured.


Pressure improves CVMore peaks, better CV




2 mg is too high



0.2 mg is too low

Primary Lipid PopulP NPressure vs No pres

ation AnalysisLC MS ESssure, LC-MS, ES-

Primary Lipid PopulP NPressure vs No pres

Pressure improves i ld CV i d DCMyield, CV mixed DCM

ation AnalysisLC MS ESssure, LC-MS, ES-

Schematic Showing RelatioExtraction and Elut

onship between Fecal Lipid tion Characteristics

Untargeted metUntargeted metsemi-, or very, y

thod now looksthod now looks y, targeted…y, g

This talk This talk bottlenecks abottlenecks a

is about is about and leverageand leveragegg

SummSumm

• Lipids in pla

Lipids in mit• Lipids in mit

• Lipids in fec

marymary

asma/sera

tochondriatochondria

cal material

AcknowledAcknowled•• Brigham and Women’s and BBrigham and Women’s and B

–– YevgeniyaYevgeniya ShuruborShurubor, , UgoUgoZhou,Zhou, SophieSophie GuoGuo, Neil Ru, Neil RuZhou, Zhou, Sophie Sophie GuoGuo, Neil Ru, Neil RuCaryn Porter, Irina StavrovCaryn Porter, Irina StavrovBird, Bird, VasantVasant MarurMarur, Matt S, Matt S

•• Outside CollaboratorsOutside Collaborators–– Walter Willett, Sue HankinsWalter Willett, Sue Hankins–– Wayne Matson, Karen Wayne Matson, Karen VignVign–– Tom Tom VoglVogl

•• FundingFunding–– NIHNIH–– Brigham and Women’s HoBrigham and Women’s Ho

Research Initiative, Burke Research Initiative, Burke

dgementsdgementsBurke/CornellBurke/Cornell

PaolucciPaolucci, , HonglianHonglian Shi, Shi, RuiwenRuiwenussell, Heather Greenberg,ussell, Heather Greenberg,ussell, Heather Greenberg, ussell, Heather Greenberg, vskaya, Diane Sheldon, Susan vskaya, Diane Sheldon, Susan

Sniatynski, Sniatynski, Rose GathunguRose Gathungu

son, Frank son, Frank HuHu, Paul , Paul VourosVourosneauneau--Callahan, Paul Callahan, Paul MilburyMilbury

ospital, Lamas Hydrocephalus ospital, Lamas Hydrocephalus Medical Research InstituteMedical Research Institute

li id i p fili ilipidomics profiling in bi l i l m t i ... · pm p1 p3 p10 n1 n3 n10 ht drug dose...

Documents